304 related articles for article (PubMed ID: 29959373)
1. The role of B7-1 in proteinuria of glomerular origin.
Novelli R; Benigni A; Remuzzi G
Nat Rev Nephrol; 2018 Sep; 14(9):589-596. PubMed ID: 29959373
[TBL] [Abstract][Full Text] [Related]
2. Podocyte-Targeted Treatment for Proteinuric Kidney Disease.
Mundel P
Semin Nephrol; 2016 Nov; 36(6):459-462. PubMed ID: 27987545
[No Abstract] [Full Text] [Related]
3. Any value of podocyte B7-1 as a biomarker in human MCD and FSGS?
Novelli R; Gagliardini E; Ruggiero B; Benigni A; Remuzzi G
Am J Physiol Renal Physiol; 2016 Mar; 310(5):F335-41. PubMed ID: 26697986
[TBL] [Abstract][Full Text] [Related]
4. CD80 Insights as Therapeutic Target in the Current and Future Treatment Options of Frequent-Relapse Minimal Change Disease.
Teh YM; Lim SK; Jusoh N; Osman K; Mualif SA
Biomed Res Int; 2021; 2021():6671552. PubMed ID: 33506028
[TBL] [Abstract][Full Text] [Related]
5. Abatacept in B7-1-positive proteinuric kidney disease.
Yu CC; Fornoni A; Weins A; Hakroush S; Maiguel D; Sageshima J; Chen L; Ciancio G; Faridi MH; Behr D; Campbell KN; Chang JM; Chen HC; Oh J; Faul C; Arnaout MA; Fiorina P; Gupta V; Greka A; Burke GW; Mundel P
N Engl J Med; 2013 Dec; 369(25):2416-23. PubMed ID: 24206430
[TBL] [Abstract][Full Text] [Related]
6. Minimal change nephropathy and focal segmental glomerulosclerosis.
Mathieson PW
Semin Immunopathol; 2007 Nov; 29(4):415-26. PubMed ID: 17955243
[TBL] [Abstract][Full Text] [Related]
7. Podocyte Expression of B7-1/CD80: Is it a Reliable Biomarker for the Treatment of Proteinuric Kidney Diseases with Abatacept?
Salant DJ
J Am Soc Nephrol; 2016 Apr; 27(4):963-5. PubMed ID: 26400567
[No Abstract] [Full Text] [Related]
8. Glomerular endothelial cells and podocytes can express CD80 in patients with minimal change disease during relapse.
Cara-Fuentes G; Venkatareddy M; Verma R; Segarra A; Cleuren AC; Martínez-Ramos A; Johnson RJ; Garg P
Pediatr Nephrol; 2020 Oct; 35(10):1887-1896. PubMed ID: 32399663
[TBL] [Abstract][Full Text] [Related]
9. Roles of microRNAs in renal disorders related to primary podocyte dysfunction.
Iranzad R; Motavalli R; Ghassabi A; Pourakbari R; Etemadi J; Yousefi M
Life Sci; 2021 Jul; 277():119463. PubMed ID: 33862110
[TBL] [Abstract][Full Text] [Related]
10. The costimulatory receptor B7-1 is not induced in injured podocytes.
Baye E; Gallazzini M; Delville M; Legendre C; Terzi F; Canaud G
Kidney Int; 2016 Nov; 90(5):1037-1044. PubMed ID: 27528551
[TBL] [Abstract][Full Text] [Related]
11. Urinary CD80 as a Replacement for Renal Biopsy for Diagnosis of Pediatric Minimal Change Disease.
Ahmed HM; Ezzat DA; Doudar NA; Adel M
Iran J Kidney Dis; 2018 Mar; 12(2):107-111. PubMed ID: 29507273
[TBL] [Abstract][Full Text] [Related]
12. B7-1 Blockade Does Not Improve Post-Transplant Nephrotic Syndrome Caused by Recurrent FSGS.
Delville M; Baye E; Durrbach A; Audard V; Kofman T; Braun L; Olagne J; Nguyen C; Deschênes G; Moulin B; Delahousse M; Kesler-Roussey G; Beaudreuil S; Martinez F; Rabant M; Grimbert P; Gallazzini M; Terzi F; Legendre C; Canaud G
J Am Soc Nephrol; 2016 Aug; 27(8):2520-7. PubMed ID: 26701979
[TBL] [Abstract][Full Text] [Related]
13. Assessment of urinary angiotensinogen as a marker of podocyte injury in proteinuric nephropathies.
Eriguchi M; Yotsueda R; Torisu K; Kawai Y; Hasegawa S; Tanaka S; Noguchi H; Masutani K; Kitazono T; Tsuruya K
Am J Physiol Renal Physiol; 2016 Feb; 310(4):F322-33. PubMed ID: 26632605
[TBL] [Abstract][Full Text] [Related]
14. Morphologic Analysis of Urinary Podocytes in Focal Segmental Glomerulosclerosis.
Shirai Y; Miura K; Yokoyama T; Horita S; Nakayama H; Seino H; Ando T; Shiratori A; Yabuuchi T; Kaneko N; Ishiwa S; Ishizuka K; Hara M; Hattori M
Kidney360; 2021 Mar; 2(3):477-486. PubMed ID: 35369007
[TBL] [Abstract][Full Text] [Related]
15. Urinary CD80: a biomarker for a favorable response to corticosteroids in minimal change disease.
Cara-Fuentes G; Lanaspa MA; Garcia GE; Banks M; Garin EH; Johnson RJ
Pediatr Nephrol; 2018 Jul; 33(7):1101-1103. PubMed ID: 29492674
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of T-cell activation by the CTLA4-Fc Abatacept is sufficient to ameliorate proteinuric kidney disease.
Herrera M; Söderberg M; Sabirsh A; Valastro B; Mölne J; Santamaria B; Valverde AM; Guionaud S; Heasman S; Bigley A; Jermutus L; Rondinone C; Coghlan M; Baker D; Quinn CM
Am J Physiol Renal Physiol; 2017 Apr; 312(4):F748-F759. PubMed ID: 27440778
[TBL] [Abstract][Full Text] [Related]
17. CD80 expression and infiltrating regulatory T cells in idiopathic nephrotic syndrome of childhood.
Eroglu FK; Orhan D; İnözü M; Duzova A; Gulhan B; Ozaltin F; Topaloglu R
Pediatr Int; 2019 Dec; 61(12):1250-1256. PubMed ID: 31513327
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of abatacept treatment for focal segmental glomerulosclerosis and minimal change disease: A systematic review of case reports, case series, and observational studies
.
Hansrivijit P; Puthenpura MM; Ghahramani N
Clin Nephrol; 2020 Sep; 94(3):117-126. PubMed ID: 32589135
[TBL] [Abstract][Full Text] [Related]
19. Direct Effects of Immunomodulatory Agents on Podocytes in Immune-Mediated Glomerular Diseases.
Manabe S; Nitta K; Nagata M
Contrib Nephrol; 2018; 195():131-142. PubMed ID: 29734158
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory smads and tgf-Beta signaling in glomerular cells.
Schiffer M; Schiffer LE; Gupta A; Shaw AS; Roberts IS; Mundel P; Böttinger EP
J Am Soc Nephrol; 2002 Nov; 13(11):2657-66. PubMed ID: 12397035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
